According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.95267. At the end of 2023 the company had a P/S ratio of 4.08.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.08 | 26.93% |
2022 | 3.21 | -20.32% |
2021 | 4.03 | -36.08% |
2020 | 6.31 | 13.98% |
2019 | 5.53 | -19.92% |
2018 | 6.91 | -65.24% |
2017 | 19.9 | -11.96% |
2016 | 22.6 | -34.72% |
2015 | 34.6 | 207.89% |
2014 | 11.2 | -68.88% |
2013 | 36.1 | 104.02% |
2012 | 17.7 | 698.31% |
2011 | 2.22 | -54.29% |
2010 | 4.85 | -7.48% |
2009 | 5.24 | 16.52% |
2008 | 4.50 | -43.54% |
2007 | 7.97 | -9.01% |
2006 | 8.76 | -15.35% |
2005 | 10.3 | -23.26% |
2004 | 13.5 | 38.21% |
2003 | 9.75 | -9.02% |
2002 | 10.7 | -52.9% |
2001 | 22.8 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.09 | 3.53% | ๐บ๐ธ USA |
Pfizer PFE | 2.69 | -31.97% | ๐บ๐ธ USA |
Amgen AMGN | 5.44 | 37.70% | ๐บ๐ธ USA |
Sanofi SNY | 2.46 | -37.87% | ๐ซ๐ท France |
Merck MRK | 5.55 | 40.43% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 2.39 | -39.47% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.32 | -41.29% | ๐ฌ๐ง UK |
Curis CRIS | 6.39 | 61.72% | ๐บ๐ธ USA |
AVEO Oncology
AVEO | 5.53 | 39.87% | ๐บ๐ธ USA |